Treatment compliance and severe adverse events limit the use of tyrosine kinase inhibitors in refractory thyroid cancer
Pazaitou-Panayiotou, Kalliopi, Chrisoulidou, Alexandra, Mandanas, Stylianos, Mathiopoulou, Lemonia, Boudina, Maria, Margaritidou, Efterpi, Georgopoulos, KonstantinosLanguage:
english
Journal:
OncoTargets and Therapy
DOI:
10.2147/OTT.S86322
Date:
September, 2015
File:
PDF, 333 KB
english, 2015